Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal
Biogen agreed to pay $300m upfront to buy a Phase II-ready tau antibody from Bristol. The plan is to move rapidly into mid-stage clinical trials for Alzheimer's disease and progressive supranuclear palsy.
You may also be interested in...
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.